^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Epic Sciences

i
Other names: Epic Sciences | Epic Sciences Inc | Epic Sciences Inc. | Epic Sciences, Inc.
Related tests:
Evidence

News

12ms
Epic Sciences announces Medicare coverage for breast-cancer focused ctDNA gene panel (Epic Sciences Press Release)
"Epic Sciences, Inc. announced...that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer."
Medicare • Reimbursement
|
DefineMBC™
1year
Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC (Businesswire)
"Epic Sciences...has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. The company will use the capital from this additional round of private investment to fund the commercial infrastructure required to commercialize the three component tests of DefineMBC, which together provide a comprehensive blood-based biopsy result for patients with metastatic breast cancer."
Financing
|
DefineMBC™
almost2years
Epic Sciences raises $43M in first close of Series F Financing to advance comprehensive profiling for metastatic cancer patients (Epic Sciences Press Release)
"Epic Sciences, Inc...has completed a $43 million first close of its Series F financing. The company will use the capital from this additional round of private investment to continue to advance its multi-omic platform and expand operations in areas such as single-cell sequencing and data analytics infrastructure."
Financing
|
DefineMBC™
almost2years
Epic Sciences’ DefineMBC™ test delivers comprehensive liquid biopsy results for metastatic breast cancer (Epic Sciences Press Release)
"Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu...DefineMBC™ includes both cell-based and cell-free analysis from a single blood draw to provide comprehensive profiling of metastatic breast cancer when a tissue biopsy result is not available."
Clinical
|
DefineMBC™
2years
Epic Sciences and Fulgent Genetics collaborate to deliver DefineMBC™ results for metastatic breast cancer patients (Epic Sciences Press Release)
"Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics...to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test."
Licensing / partnership
|
DefineMBC™
2years
Epic Sciences, Biosplice Therapeutics partner on multiomic profiling for cancer trials (Genomeweb)
"Biosplice Therapeutics is partnering with Epic Sciences to incorporate multiomic profiling into Biosplice's clinical oncology programs, the companies said on Thursday...As part of the collaboration, Biosplice plans to use Epic's liquid biopsy platform to characterize drug activity and patient response for its Cirtuvivint (SM08502) investigative drug in two clinical trials."
Licensing / partnership
over2years
Epic Sciences unveils DefineMBC™, a novel blood-based test designed to improve care for metastatic breast cancer patients (PRNewswire)
"Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available...DefineMBC combines several multi-analyte assay methods to perform comprehensive cancer profiling and has demonstrated impressive sensitivity, specificity, accuracy, and precision."
Clinical
|
DefineMBC™
over2years
EPIC sciences platform demonstrates compelling value of cell analysis in data presented at San Antonio Breast Cancer Symposium 2021 (PRNewswire)
"Epic Sciences, Inc. (Epic)'s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate...Poster P2-02-03 Circulating tumor cells (CTCs), CTC heterogeneity and distinct morphological CTC phenotypes predict worse survival in metastatic breast cancer (MBC)"
Clinical data